Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow RAPT Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for RAPT Therapeutics, Inc.

RAPT

RAPT Therapeutics, Inc.

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a biopharmaceutical company focused on discovering and developing immunology-based therapies for inflammatory and immunological diseases. Its core pipeline includes monoclonal antibodies and small molecules targeting IgE and CCR4 pathways, aiming to treat allergies, CSU, asthma, and cancers like NSCLC. The company leverages strategic licensing and collaborations to advance innovative treatments with potential competitive advantages in efficacy, safety, and dosing.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from RAPT Therapeutics, Inc.

1
1
RAPT Therapeutics, Inc. RAPT Therapeutics Reports $17.6 Million Net Loss in Q3 2025, Sees Improvement in Financial Position

Via official filing (AI summary) | 8 months ago | 0 comments

2
1
RAPT Therapeutics, Inc. RAPT Therapeutics Reports Improved Q2 2025 Net Loss of $17.6 Million

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
RAPT Therapeutics, Inc. RAPT Therapeutics Reports $17.2 Million Net Loss, Improves Operating Expenses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
RAPT Therapeutics, Inc. RAPT Therapeutics Reports $129.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
RAPT Therapeutics, Inc. RAPT Therapeutics Reports Decline in Cash and Assets, Net Loss Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments